Biomarkers of Pulmonary Hypertension
What are informative and clinically relevant biomarkers of pulmonary hypertension (PH)?
What are informative and clinically relevant biomarkers of pulmonary hypertension (PH)?
How can the safety, dosing and benefits of existing therapies for sickle cell disease such as hydroxyurea, be optimized in order to increase its efficacy and improve patient adherence?
Goal 3: Advance Translational Research
Would anti-angiogenic therapeutics prevent patients with pulmonary hypertension from worsening?
What triggers decompensation of cellular and molecular pathways during exacerbations of chronic lung diseases?
Goal 4: Develop Workforce and Resources
Goal 3: Advance Translational Research
What is the comparative effectiveness of short-term vs. chronic (e.g. 12 mos) pulmonary rehabilitation on survival, patient-reported outcomes (symptom frequency, activities of daily living, quality of life, sleep quality, exacerbations), healthcare utilization, and costs from a societal and healthcare system perspective?
Can pulmonary rehabilitation change the course of COPD? Is pulmonary rehabilitation a disease-modifying therapy? Does pulmonary rehabilitation improve survival? Does pulmonary rehabilitation reduce readmissions?